Sheffield, UK, April 2024: SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced it has secured £1.8M in seed funding from the University of Sheffield, UKRI,Takeda, and a consortium of angel investors.
SynGenSys is a spin-out company from the University of Sheffield designing synthetic promoters and signal peptides for precise engineering of gene expression control. The funding will support the company to expand its portfolio of off-the-shelf promoter systems, and extend its capacity for custom-promoter projects, for both biopharma manufacturing and cell and gene therapy application areas.
